Comparative study of a novel selective urate reabsorption inhibitor "dotinurad" among patient groups with different stages of renal dysfunction.

ABSTRACT:

Background

Dotinurad is a selective urate reabsorption inhibitor (SURI), which selectively inhibits URAT1 to lower serum uric acid levels in patients with hyperuricemia. Herein, the effects of dotinurad were compared among patient groups with different stages of renal dysfunction.

Methods

Patient data from four clinical trials were pooled and divided into four groups according to the stage of renal dysfunction to compare the effects of dotinurad at different stages. The grouping (stages G1-G3b) was based on the estimated glomerular filtration rate (eGFR) of the patients. In addition, patient data from a long-term study (34 or 58 weeks) were evaluated in the same manner.

Results

In the pooled analysis, the percentage of patients achieving a serum uric acid level of ≤ 6

SUBMITTER: Takahashi T 

PROVIDER: S-EPMC8526486 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature